Jefferies Reiterates Buy on Bio-Rad Labs (BIO) After Reviewing Job Listings

December 1, 2016 9:04 AM EST
Get Alerts BIO Hot Sheet
Price: $188.46 --0%

Rating Summary:
    4 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade BIO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies reiterated a Buy rating and $225.00 price target on Bio-Rad Labs (NYSE: BIO) after reviewing the company's job listings. It appears the company may have finished hiring a handful of "lean six sigma black belt process specialists" at its headquarters in Hercules, CA. Also, a new job listing posted yesterday indicates BIO is looking to add a new regulatory affairs manager who will specifically be responsible for "developing, submitting & obtaining FDA clearance for DNA sequencing & ddPCR (droplet digital PCR) IVD devices".

Analyst Brandon Couillard commented, "Our review of BIO's online job listings revealed two key incremental data points: 1) it appears to have finished hiring several new lean six sigma process experts at its Hercules, CA headquarters; and, 2) a new listing (FDA affairs manager role) suggests BIO's targeted DNA sequencing pipeline program may have reached a key development milestone & taken a step closer to commercialization. BIO remains our top pick."

For an analyst ratings summary and ratings history on Bio-Rad Labs click here. For more ratings news on Bio-Rad Labs click here.

Shares of Bio-Rad Labs closed at $173.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment